29331-92-8 Usage
Description
10,11-DIHYDRO-10-HYDROXYCARBAZEPINE, also known as 10,11-dihydro-10-hydroxy Carbamazepine, is a dibenzoazepine compound that is 5H-dibenzo[b,f]azepine, reduced across the C-10,11 positions, and carrying a carbamoyl substituent at the azepine nitrogen and a hydroxy function at C-10. It is a white solid with anticonvulsant and mood-stabilizing effects, and is an active metabolite of oxcarbazepine.
Uses
Used in Pharmaceutical Industry:
10,11-DIHYDRO-10-HYDROXYCARBAZEPINE is used as an active metabolite of oxcarbazepine for its anticonvulsant efficacy. It is rapidly and almost completely converted from oxcarbazepine and modulates several ion channels and receptors to demonstrate its therapeutic effects.
10,11-DIHYDRO-10-HYDROXYCARBAZEPINE is used as a voltage-gated sodium channel blocker for its ability to inhibit both voltage-gated Na+ and Ca2+ channels, which contributes to its anticonvulsant properties.
10,11-DIHYDRO-10-HYDROXYCARBAZEPINE is used as a modulator of voltage-gated K+ channels for its ability to potentiate these channels, further enhancing its anticonvulsant effects.
10,11-DIHYDRO-10-HYDROXYCARBAZEPINE is used as an adenosine A1 receptor antagonist, which may contribute to its therapeutic effects.
10,11-DIHYDRO-10-HYDROXYCARBAZEPINE is used to increase dopaminergic transmission, which may have mood-stabilizing effects.
10,11-DIHYDRO-10-HYDROXYCARBAZEPINE is used as a glutamate release inhibitor, which can help in managing neurological conditions by reducing excitotoxicity.
Check Digit Verification of cas no
The CAS Registry Mumber 29331-92-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,9,3,3 and 1 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 29331-92:
(7*2)+(6*9)+(5*3)+(4*3)+(3*1)+(2*9)+(1*2)=118
118 % 10 = 8
So 29331-92-8 is a valid CAS Registry Number.
InChI:InChI=1/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19)
29331-92-8Relevant articles and documents
Baker et al.
, p. 703 (1973)
Brain-targeting eslicarbazepine ester prodrug and application thereof
-
Paragraph 0093; 0094; 0095; 0096, (2017/08/28)
The invention relates to an eslicarbazepine ester prodrug and an application thereof, wherein the prodrug is a compound represented by the formula (I) or optical isomers or physiologically acceptable salts of the compound represented by the formula (I), wherein R represents a lipophilic substituent. The compound represented by the formula (I) is the eslicarbazepine ester prodrug containing the lipophilic substituent, is converted into eslicarbazepine through metabolism in vivo to play pharmacological effects, and can be applied in preparation of drugs for treatment, prevention or adjuvant treatment of central nervous system diseases, such as epilepsy and the like.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
-
, (2016/06/01)
The invention relates to the compounds of formula I and formula IA or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I and formula IA; and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder (ADHD), schizophrenia, neuropathic pain, seizures, bipolar disorder, mania, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotonia, intermittent explosive disorder, borderline personality disorder, Myotonia congenita and post-traumatic stress disorder.